PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Respirology10.1111/resp.14150_603202126S3324-324P8‐91: Anti‐PD‐1/PD‐L1 antibody plus chemotherapy after platinum‐based chemotherapy in patients with advanced non‐small cell lung cancerhttps://onlinelibrary.wiley.com/doi/pdf/10.1111/resp.14150_603, https://onlinelibrary.wiley.com/doi/full-xml/10.1111/resp.14150_603, https://onlinelibrary.wiley.com/doi/pdf/10.1111/resp.14150_603
Current Oncology10.3390/curroncol2806043720212865227-5239The Challenge to the Pathologist of PD-L1 Expression in Tumor Cells of Non-Small-Cell Lung Cancer—An OverviewKorinna Jöhrens, Josef Rüschoffhttps://www.mdpi.com/1718-7729/28/6/437/pdf
10.21203/rs.3.rs-79433/v12020Atezolizumab Plus Chemotherapy Vs Chemotherapy Alone for Non-small Cell Lung Cancer: A Meta-analysis of Different PD-L1-expression LevelsZhang Hong, Zhong Xiaoyu, Liu Zhaowei, Miao Feifei, Zhang Changgenghttps://www.researchsquare.com/article/rs-79433/v1, https://www.researchsquare.com/article/rs-79433/v1.html
Lung Cancer10.1016/0169-5002(91)90355-a199174273Tumor-tissue and plasma concentrations of platinum during chemotherapy of non-small-cell lung cancer patientshttps://api.elsevier.com/content/article/PII:016950029190355A?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:016950029190355A?httpAccept=text/plain
Lung Cancer10.1016/s0169-5002(09)70259-4200964S57136P PLATINUM BASED CHEMOTHERAPY IN STAGE IIIB AND IV NON-SMALL CELL LUNG CANCER (NSCLC) – THE EFFECT ON SURVIVALN.A. Mobarekhttps://api.elsevier.com/content/article/PII:S0169500209702594?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0169500209702594?httpAccept=text/plain
Lung Cancer10.1016/j.lungcan.2020.07.012202014791-98Spatial heterogeneity of PD-L1 expression and the risk for misclassification of PD-L1 immunohistochemistry in non-small cell lung cancerShani Ben Dori, Asaf Aizic, Edmond Sabo, Dov Hershkovitzhttps://api.elsevier.com/content/article/PII:S0169500220305341?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0169500220305341?httpAccept=text/plain
Lung Cancer10.1016/s0169-5002(05)80412-x200549S90PD-079 Should chemotherapy combinations for advanced non-small cell lung cancer (NSCLC) be platinum-based? A literature-based meta-analysis of phase III randomised trialsJ. Pujol, F. Barlesi, J. Daureshttps://api.elsevier.com/content/article/PII:S016950020580412X?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S016950020580412X?httpAccept=text/plain
Lung Cancer10.1016/j.lungcan.2019.08.0232019136136-144PD-L1 expression on tumor-infiltrating immune cells is highly associated with M2 TAM and aggressive malignant potential in patients with resected non-small cell lung cancerRyota Sumitomo, Tatsuya Hirai, Masaaki Fujita, Hiroaki Murakami, Yosuke Otake, Cheng-long Huanghttps://api.elsevier.com/content/article/PII:S0169500219306245?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0169500219306245?httpAccept=text/plain
Lung Cancer10.1016/j.lungcan.2017.06.006201711063-67MYC expression correlates with PD-L1 expression in non-small cell lung cancerEun Young Kim, Arum Kim, Se Kyu Kim, Yoon Soo Changhttps://api.elsevier.com/content/article/PII:S0169500217303598?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0169500217303598?httpAccept=text/plain
Cancer Genetics10.1016/j.cancergen.2019.06.001201923710-18PD-L1 gene copy number and promoter polymorphisms regulate PD-L1 expression in tumor cells of non-small cell lung cancer patientsPaweł Krawczyk, Anna Grenda, Kamila Wojas-Krawczyk, Marcin Nicoś, Tomasz Kucharczyk, Bożena Jarosz, Katarzyna Reszka, Juliusz Pankowski, Kinga Krukowska, Aleksandra Bożyk, Justyna Szumiło, Marek Sawicki, Tomasz Trojanowski, Janusz Milanowskihttps://api.elsevier.com/content/article/PII:S2210776219300249?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S2210776219300249?httpAccept=text/plain